Table 3 Test results and outcomes
|  | Total Cohort n = 159 |
|---|---|
Abnormal functional testing | 17 (10.7%) |
 Positive | 12 (7.5%) |
 Inconclusive | 5 (3.1%) |
CAC present | 59 (37.1%) |
 Mild | 42 (26.4%) |
 Moderate | 15 (9.4%) |
 Severe | 2 (1.3%) |
Rest left ventricular ejection fraction (%)a | 60 (55 – 65) |
Stress left ventricular ejection fraction (%)b | 69.5 (61 – 74) |
2019 ACC/AHA Guideline on the Primary Prevention of CV Disease recommended discussion regarding statin therapy | 23 (15.2%) |
MACE during follow-up period | 38 (23.9%) |
 Coronary revascularization | 18 |
 Hospitalization for heart failure | 9 |
 Hospitalization for nonfatal myocardial infarction | 5 |
 Hospitalization for ischemic stroke | 4 |
 Cardiovascular death | 2 |
Years to MACE from functional testing | 3.3 (0.9 – 6.9) |
Years to MACE from HL diagnosis | 30.5 (21 – 35) |